{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:15:26Z","timestamp":1778667326227,"version":"3.51.4"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Objective<\/jats:title>\n \n Vitamin K\n 1<\/jats:sub>\n (VK\n 1<\/jats:sub>\n ) supplementation is an important therapeutic agent for the treatment of hemorrhage due to VK\n 1<\/jats:sub>\n deficiency. It can be administered orally, intramuscularly, or via intravenous injection. This study was conducted to evaluate the bioequivalence of VK\n 1<\/jats:sub>\n micelle produced by Hainan Biotech Pharmaceutical Co., Ltd. compared to the original drug KONAKION\u00aeMM when administered orally.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This was a randomized, open-label, two-period, single-dose, crossover bioequivalence study conducted under both fasting and fed conditions, with 28 participants in each condition. Participants received 10\u00a0mg oral dose of test (T) or reference (R) drug in the first period and the opposite drug in the second period, with a 9-day washout. Blood concentrations of the E and Z isomers of VK\n 1<\/jats:sub>\n were measured at 26 or 29 time points for fasting condition or fed condition, respectively. Bioequivalence was determined if the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of the peak concentration (C\n max<\/jats:sub>\n ), the area under the concentration-time curve from time zero to the last measurable concentration (AUC\n 0\u2013t<\/jats:sub>\n ) and the extrapolated area under the curve from time zero to infinity (\n \n \n \n \n AUC<\/mml:mtext>\n \n 0<\/mml:mn>\n \u2212<\/mml:mo>\n \u221e<\/mml:mi>\n <\/mml:mrow>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:inline-formula>\n ) after log transformation for VK\n 1<\/jats:sub>\n E isomer fell within the 80.00%\u2013125.00% range under both fasting and fed conditions. The International Normalized Ratio (INR) was used as an exploratory endpoint to observe changes following dosing. Safety assessments included vital signs and electrocardiograms (ECGs).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Under fasting conditions, the 90% CIs for the GMRs of C\n max<\/jats:sub>\n , AUC\n 0-t<\/jats:sub>\n , and\n \n \n \n \n AUC<\/mml:mtext>\n \n 0<\/mml:mn>\n \u2212<\/mml:mo>\n \u221e<\/mml:mi>\n <\/mml:mrow>\n <\/mml:msub>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:inline-formula>\n for the VK\n 1<\/jats:sub>\n E isomer were 99.17%\u2013119.24%, 103.91%\u2013121.13%, and 105.72%\u2013122.77%, respectively. Under fed conditions, the corresponding 90% CIs were 83.56%\u2013120.82%, 84.98%\u2013124.63%, and 83.97%\u2013124.32%. All values fell within the 80.00%\u2013125.00% equivalence margin, confirming bioequivalence between the two formulations. There were no significant changes in INR. The safety profile was favorable, with no serious adverse events (SAEs) or grade 3 or higher adverse events (AEs) reported.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n The VK\n 1<\/jats:sub>\n micelle produced by Hainan Brilliant Pharmaceutical Co., Ltd. is bioequivalent to the original drug KONAKION\u00aeMM, supporting its approval as a generic product by oral administration. It demonstrated good safety and tolerability in healthy Chinese subjects.\n <\/jats:p>\n <\/jats:sec>\n \n Clinical Trial Registration<\/jats:title>\n \n http:\/\/www.chinadrugtrials.org.cn\/index.html<\/jats:ext-link>\n , identifier CTR20223408;\n https:\/\/www.chictr.org.cn\/<\/jats:ext-link>\n , identifier ChiCTR2500096211.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2026.1802709","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:36:50Z","timestamp":1778665010000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A randomized, open, two-period, cross-over, single oral dose, pharmacokinetics and bioequivalence study of vitamin K1 in healthy volunteers under fasting and fed conditions"],"prefix":"10.3389","volume":"17","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[{"name":"Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Qi","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinjuan","family":"Li","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Zhong","sequence":"additional","affiliation":[{"name":"Hainan Brilliant Pharmaceutical Co., Ltd.","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghe","family":"Wang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1160\/TH09-12-0822","article-title":"Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study","volume":"104","author":"Crowther","year":"2010","journal-title":"Thromb. Haemost."},{"key":"B2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1182\/asheducation-2016.1.605","article-title":"Reversing vitamin K antagonists: making the old new again","volume":"2016","author":"Eichinger","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B3","unstructured":"Draft guidance on phytonadione\n \n \n 2015"},{"key":"B4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1079\/bjn19960027","article-title":"Effect of food composition on vitamin K absorption in human volunteers","volume":"76","author":"Gijsbers","year":"1996","journal-title":"Br. J. Nutr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"109071","DOI":"10.1016\/j.bioelechem.2025.109071","article-title":"Electrochemical regulation of mitochondrial respiratory chain protein redox states using transmembrane copper peptides for myocardial infarction risk assessment","volume":"167","author":"Hao","year":"2026","journal-title":"Bioelectrochemistry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1345\/aph.1Q769","article-title":"Use of oral vitamin K for prevention of late vitamin k deficiency bleeding in neonates when injectable vitamin K is not available","volume":"46","author":"Ipema","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1017\/S0007114509371688","article-title":"The effect of different meals on the absorption of stable isotope-labelled phylloquinone","volume":"102","author":"Jones","year":"2009","journal-title":"Br. J. Nutr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1001\/archinte.163.20.2469","article-title":"Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study","volume":"163","author":"Lubetsky","year":"2003","journal-title":"Arch. Intern Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00228-012-1362-y","article-title":"VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation","volume":"69","author":"Marinova","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1891\/0730-0832\/11-T-630","article-title":"Vitamin K deficiency bleeding: an ounce of prevention","volume":"39","author":"McPherson","year":"2020","journal-title":"Neonatal Netw."},{"key":"B11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/MPG.0000000000001232","article-title":"Prevention of vitamin K deficiency bleeding in newborn infants: a position paper by the ESPGHAN committee on nutrition","volume":"63","author":"Mihatsch","year":"2016","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/nutrit\/nuab061","article-title":"Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity","volume":"80","author":"Mlad\u011bnka","year":"2022","journal-title":"Nutr. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s13312-025-3374-6","article-title":"One milligram Versus two milligram intramuscular vitamin K to prevent late-onset hemorrhagic disease in young infants: a randomized controlled trial","volume":"62","author":"Natarajan","year":"2025","journal-title":"Indian Pediatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e14141","DOI":"10.1111\/eci.14141","article-title":"Vitamin K insufficiency and the prophylaxis strategy in term healthy infants: a multicentre study","volume":"54","author":"Perrone","year":"2024","journal-title":"Eur. J. Clin. Invest."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1111\/jth.12753","article-title":"Vitamin K1 in oral solution or tablets: a crossover trial and two randomized controlled trials to compare effects","volume":"12","author":"van Rein","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e00299","DOI":"10.1002\/advs.202500299","article-title":"Injectable BMSC-based extracellular matrix-mimicking microtissue for myocardial infarction repair","volume":"13","author":"Yao","year":"2026","journal-title":"Adv. Sci. (Weinh)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00228-021-03127-8","article-title":"Randomized, placebo-controlled trial of orally administered vitamin K1 for warfarin-associated coagulopathy in Chinese patients with mechanical heart valves","volume":"77","author":"Zhang","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1802709\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:36:55Z","timestamp":1778665015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1802709\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":17,"alternative-id":["10.3389\/fphar.2026.1802709"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1802709","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1802709"}}